Clinical research
The case for the Philippines
Cost, scale, English fluency, and a regulatory pathway that is actually navigable.
30–50%
Lower per-patient cost
Same protocol, materially smaller site budget
Phase I–IV
Plus non-interventional
Feasibility through closeout
No fee to you
Paid by the partner CRO
You know my incentive before you weigh my advice
A 30–50% reduction in per-patient cost, without cutting quality corners. Range reflects therapeutic area and site mix.
Four conditions, rarely aligned
Four conditions rarely hold at once. Where they do, sponsors move trial volume — and Southeast Asia is where they have been moving it.
30–50%Cost reduction
Lower per-patient cost
Run the same protocol against a materially smaller site budget. The saving comes from local cost structure, not from thinner monitoring or reduced source verification.
100M+Population
English-speaking, largely treatment-naïve
Consent documents and case report forms need no translation layer. A treatment-naïve pool means cleaner signal and fewer washout exclusions at screening.
ICH-GCPStandard
Trained investigators, accredited sites
GCP-certified principal investigators at facilities that global sponsors already contract with. This is the question your QA group will ask first, so it is the one I document first.
PH FDARegulator
A defined submission route
Philippine FDA and ethics committee review follow a published sequence. Knowing where it stalls — and who to call when it does — is most of the value of a local advisor.
Engagement sequence
Three steps, in order. You skip the RFP cycle.
I handle vendor scouting, screening, and negotiation, so you land with the right partner the first time instead of the third.
You tell me the study
Therapeutic area, phase, target enrollment, budget envelope, and your timeline constraints. Thirty minutes is usually enough.
Output — a candid read on whether the Philippines fitsI shortlist and negotiate
I run competitive proposals across vetted Philippine CROs and negotiate pricing and timelines on your behalf. You see the comparison, including the partners I ruled out and why.
Output — a costed shortlist with negotiated termsYou sign; I stay on
You contract directly with the CRO. I remain engaged as your local advisor through startup and execution — the person who reads the room when a site goes quiet.
Output — ongoing local representation
Next step
Start with thirty minutes.
Enough to get a candid read on whether the Philippines fits your protocol — including the case against, if there is one.